Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3729383 | 0.94 | ELANE (0.63) | ELANEGAACYP1A2CYP2C9PKM | |
| SCHEMBL21325759 | 0.92 | ELANE (0.70) | ELANEGAACYP1A2CYP2C9PKM | |
| SCHEMBL29187166 | 0.88 | ELANE (0.72) | ELANEGAAMAPTLMNATDP1 | |
| SCHEMBL514357 | 0.88 | ELANE (0.72) | ELANEGAAMAPTLMNATDP1 | |
| SCHEMBL12751388 | 0.87 | ELANE (0.58) | ELANEGAACYP1A2CYP2C9PKM | |
| Hydrochloric Acid SCHEMBL25243908 | 0.86 | ELANE (0.70) | ELANEGAAMAPTLMNATDP1 | |
| SCHEMBL30894420 | 0.86 | ELANE (0.70) | ELANEGAAMAPTLMNATDP1 | |
| SCHEMBL21795326 | 0.85 | ELANE (0.79) | ELANEPKMMAPTLMNAHSD17B10 | |
| SCHEMBL20798189 | 0.85 | GAA (0.54) | ELANEGAACYP1A2CYP2C9PKM | |
| SCHEMBL13765245 | 0.85 | ELANE (0.61) | ELANEGAACYP1A2CYP2C9PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739047-B2 | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739047-B2 | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210179535-A1 | ALPHA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-06-17 | — | — | US | disclosed |
| US-10968163-B2 | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-04-06 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| US-8182975-B2 | Positive resist composition and pattern forming method using the same | FUJIFILM CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20080248419-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1633306-A4 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO INC (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1633306-A2 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | Merck & Co., Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105698-A2 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO., INC. (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179535-A1 | ALPHA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | FABP1, FABP2, FABP4 | ELANE 3517/4885GAA 2638/4885CYP1A2 2127/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | ELANE 254/4885GAA 19/4885CYP1A2 2500/4885 |
| US-10968163-B2 | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | FABP1, FABP2, FABP4 | ELANE 3688/4885GAA 2726/4885CYP1A2 2006/4885 |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | ELANE 254/4885GAA 19/4885CYP1A2 2500/4885 |
| US-11739047-B2 | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | FABP1, FABP2, FABP4 | ELANE 3517/4885GAA 2638/4885CYP1A2 2127/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | ELANE 412/4885GAA 19/4885CYP1A2 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.